Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) watched its stock plummet 20% after slashing its full-year sales and profit outlook for the second time this year. The announcement, ahead of the full Q2 2025 results due Aug. 6, reported 18% sales growth and 29% operating profit growth at constant exchange rates (CER) for the first half of 2025 but highlighted significant challenges.
The question remains: Is this an overreaction by the market, or a warranted reset of the stock? With shares now trading where they did in late 2022, effectively wiping out all the gains made during the Ozempic mania run-up, investors are right to ask if NVO stock is just too cheap to ignore?
This post appeared first on 24/7 Wall St.